

Announcement no 17/2008

To OMX Nordic Exchange Copenhagen and the press

Copenhagen, 2 April, 2008

Report regarding the managements' and closely related parties' transactions with securities in Exiqon A/S

Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S is required to publish the managements' and their closely related parties' transactions with shares and related securities in Exiqon A/S.

Name:	Steinar J Engelsen
Reason for reporting:	Member of Exiqon's Board of Directors
Security Code (ISIN-kode):	DK0060077758
Name of the securities:	Share
Type of transaction:	Buy
Date of trade	2 April 2008
Place of transaction:	OMX Nordic Exchange Copenhagen
Traded securities (no.):	10,000
Market value in DKK of traded securities:	353,000

Additional information

CEO Lars Kongsbak, tlf. +45 45 66 08 88 or +45 40 90 21 01

CFO Hans Henrik Chrois Christensen tlf. +45 45 66 08 88 or +45 40 90 21 31

About Exiqon

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics.

Disclaimer

Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.